May, 2023

Global
News / Press Releases
Astellas Highlights Continued Delivery of Strong Cancer Portfolio and Pipeline at 2023 ASCO Annual Meeting
Read More
Global
News / Press Releases
Astellas Announces Commitments to 3rd Phase of GHIT Fund Replenishment
TOKYO, May 25, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that it has committed to supporting the 3rd phase of the Global Health Innovative Technology Fund (GHIT Fund), together with a cross-sector group of funding partners. The cross-sector group has committed over US$200 million to the GHIT Fund. Furthermore, we have contributed to the...
Read More
Global
News / Press Releases
Astellas announces the intended decision to transfer its manufacturing plant and business based in Meppel, the Netherlands, to Delpharm
TOKYO, May 25, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that Astellas B.V. and Astellas Pharma Europe B.V., Astellas’ subsidiaries in Netherlands, have made an intended decision to sell and transfer its manufacturing plant, located in Meppel, the Netherlands (the “Business”), to Delpharm Industrie SAS (CEO: Sébastien Aguettant, “Delpharm...
Read More
Global
News / Press Releases
Notice Regarding Continuation of the Performance-linked Stock Compensation Scheme and Performance-linked Stock Delivery Scheme for the Domestic and Global Astellas Group Executives
Read More
Global
News / Press Releases
Notice Regarding Continuation of the Performance-linked Stock Compensation Scheme
Read More

May, 2023

Global
News / Press Releases
Astellas Highlights Continued Delivery of Strong Cancer Portfolio and Pipeline at 2023 ASCO Annual Meeting
Read More
Global
News / Press Releases
Astellas Announces Commitments to 3rd Phase of GHIT Fund Replenishment
TOKYO, May 25, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that it has committed to supporting the 3rd phase of the Global Health Innovative Technology Fund (GHIT Fund), together with a cross-sector group of funding partners. The cross-sector group has committed over US$200 million to the GHIT Fund. Furthermore, we have contributed to the...
Read More
Global
News / Press Releases
Astellas announces the intended decision to transfer its manufacturing plant and business based in Meppel, the Netherlands, to Delpharm
TOKYO, May 25, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that Astellas B.V. and Astellas Pharma Europe B.V., Astellas’ subsidiaries in Netherlands, have made an intended decision to sell and transfer its manufacturing plant, located in Meppel, the Netherlands (the “Business”), to Delpharm Industrie SAS (CEO: Sébastien Aguettant, “Delpharm...
Read More
Global
News / Press Releases
Notice Regarding Continuation of the Performance-linked Stock Compensation Scheme and Performance-linked Stock Delivery Scheme for the Domestic and Global Astellas Group Executives
Read More
Global
News / Press Releases
Notice Regarding Continuation of the Performance-linked Stock Compensation Scheme
Read More
Nothing Found

Unfortunately, we weren't able to find a match for your search query. Please try again.

Nothing Found

Unfortunately, we weren't able to find a match.

Back to Newsroom